CAR-T for multiple myeloma: practice pearls

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Ciltacabtagene autoleucel and idecabtagene vicleucel are transformative CAR-T cell therapies for multiple myeloma.
• The integration of these advanced therapies into routine clinical practice requires practical guidance.

Purpose of the Study:

• To provide a practical guide for clinicians on incorporating CAR-T cell therapy into multiple myeloma management.
• To highlight key clinical considerations and best practices for CAR-T therapy implementation.

Main Methods:

• This is a practical guide, not a research study; therefore, no specific methods were employed.
• Content is based on clinical expertise and current understanding of CAR-T therapy in multiple myeloma.

Main Results:

• The guide addresses critical aspects of CAR-T therapy, including expected outcomes and referral timing.
• It provides recommendations on bridging therapy, managing treatment complications, and therapeutic sequencing.
• Strategies for managing relapse after CAR-T therapy are also discussed.

Conclusions:

• CAR-T cell therapy represents a significant advancement in multiple myeloma treatment.
• Effective clinical integration requires careful attention to patient selection, management of complications, and sequencing of therapies.